A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21) - Trial NCT06295432
Access comprehensive clinical trial information for NCT06295432 through Pure Global AI's free database. This Phase 2 trial is sponsored by Dizal Pharmaceuticals and is currently Recruiting. The study focuses on Non-small Cell Lung Cancer. Target enrollment is 90 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Dizal Pharmaceuticals
Timeline & Enrollment
Phase 2
Jun 01, 2023
Jun 01, 2025
Primary Outcome
Part A: incidence of DLT , ≥grade 3 TEAEs and SAEs; Part B: incidence of ≥grade 3 TEAEs as assessed by CTCAE, incidence of SAEs.
Summary
DZD9008 in combination with AZD4205 for the treatment of patients with advanced NSCLC with
 EGFR mutations who have progressed after standard treatment. The purpose of this study is to
 assess the safety and efficacy of this combination therapy.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06295432
Non-Device Trial